Clinical Trials Logo

Resectable clinical trials

View clinical trials related to Resectable.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03805022 Recruiting - Resectable Clinical Trials

Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

CIRSARC
Start date: February 14, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to investigate whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management according to the ISG-STS 10-01 study (3 cycles of neoadjuvant doxorubicin based chemotherapy + surgery +/- radiotherapy) improves the outcome of high-risk CINSARC patients with resectable soft-tissue sarcoma (STS). Primary endpoint is metastatic progression-free survival (M-PFS, after 3 years of follow-up).